Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) has issued an announcement.
GenFleet Therapeutics (Shanghai) Inc., a Hong Kong-listed biopharmaceutical developer, reported its audited consolidated financial results for the year ended December 31, 2025, highlighting continued investment in research and development alongside a strengthened cash position. The company operates through a group structure and directs significant resources to advancing its drug pipeline.
For 2025, GenFleet’s revenue rose to RMB130.3 million from RMB104.7 million a year earlier, while research and development expenses declined to RMB282.3 million from RMB332.1 million, reflecting some cost discipline. The group’s reported net loss widened sharply to RMB1.79 billion due to non-cash items, although adjusted loss narrowed to RMB226.5 million, and cash and bank balances increased substantially to RMB2.07 billion, indicating improved funding capacity for future operations.
The announcement also noted changes to the company’s joint company secretary, authorised representative and process agent, alongside a waiver from strict compliance with certain Hong Kong listing rules. These governance and regulatory adjustments suggest ongoing efforts to align corporate structure and compliance arrangements with the company’s growth stage and listing requirements, with potential implications for investor oversight and administrative efficiency.
More about Genfleet Therapeutics (Shanghai), Inc. Class H
GenFleet Therapeutics (Shanghai) Inc. is a China-based biopharmaceutical company focused on developing innovative therapeutics, with operations and listing in Hong Kong under stock code 2595. The group concentrates its resources on research and development, supported by capital raised to fund its clinical and pre-clinical drug pipeline.
Average Trading Volume: 1,619,374
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$10.31B
For detailed information about 2595 stock, go to TipRanks’ Stock Analysis page.